AVENTYL HYDROCHLORIDE Drug Patent Profile

Which patents cover Aventyl Hydrochloride, and what generic alternatives are available?

Aventyl Hydrochloride is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in AVENTYL HYDROCHLORIDE is nortriptyline hydrochloride. There are twelve drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the nortriptyline hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aventyl Hydrochloride

A generic version of AVENTYL HYDROCHLORIDE was approved as nortriptyline hydrochloride by DR REDDYS LABS SA on March 30^th, 1992.

Summary for AVENTYL HYDROCHLORIDE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for AVENTYL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	AVENTYL HYDROCHLORIDE	nortriptyline hydrochloride	CAPSULE;ORAL	014684-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	AVENTYL HYDROCHLORIDE	nortriptyline hydrochloride	CAPSULE;ORAL	014684-002	Approved Prior to Jan 1, 1982		DISCN	No	No

International Patents for AVENTYL HYDROCHLORIDE

See the table below for patents covering AVENTYL HYDROCHLORIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	1468341
Switzerland	494730	Verfahren zur Herstellung von Dibenzocyclopentenen (Dibenzo cycloheptenes)
France	4407
Belgium	650988

AVENTYL HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is Aventyl Hydrochloride and What Are Its Therapeutic Indications?

Aventyl Hydrochloride, also known by its generic name nortriptyline hydrochloride, is a tricyclic antidepressant (TCA). It was approved for medical use in the United States in the 1960s. Its primary indications include major depressive disorder, neuropathic pain, and certain off-label uses such as migraine prophylaxis and panic disorder.

What Is the Current Market Size and Key Revenue Drivers?

The global antidepressant market was valued at approximately USD 15 billion in 2022. Aventyl Hydrochloride represents a minor segment within this space, with annual sales estimated between USD 400-600 million annually worldwide. Its revenues are segmented as follows:

• North America: 50%
• Europe: 30%
• Rest of World: 20%

The drug's market share diminishes against selective serotonin reuptake inhibitors (SSRIs) like fluoxetine and sertraline, which dominate due to improved side-effect profiles. However, Aventyl retains relevance in treatment-resistant depression and neuropathic pain.

What Are Patent and Regulatory Statuses?

Aventyl Hydrochloride is a generic medication with no active patent protections since the late 2000s. The original formulation patents expired around 2008-2010 globally, allowing multiple suppliers to produce generic versions. Regulatory approval remains active in key jurisdictions: FDA approval in the US and EMA approval in Europe.

Potential market expansion hinges on off-label indication approvals or new formulations like extended-release versions. No recent regulatory extensions or updates for Aventyl specifically are documented.

What Are the Patent Landscapes and R&D Initiatives?

Given its patent expiration, Aventyl Hydrochloride is not subject to significant new patent filings. Currently, no proprietary innovations directly related to Aventyl are in advanced clinical stages.

However, research efforts focus on:

• Developing safer delivery systems
• Combination therapies
• New indications leveraging its mechanism of serotonin and norepinephrine reuptake inhibition

These do not appear to threaten existing markets but could influence niche segments over time.

What Are the Competitive Dynamics and Market Entry Barriers?

Competitive pressures primarily stem from newer antidepressants with improved tolerability profiles:

competitor	Market share (est. 2022)	Key advantages
SSRIs	70%	Better side-effect profile
SNRIs	15%	Dual mechanism, fewer side effects
Aventyl (TCAs)	10%	Efficacy in resistant cases, cost
Other (e.g., MAOIs)	5%	Specific niche uses

Entry barriers include:

• Existing reimbursement pathways favor newer agents
• Physician preference toward newer SSRIs/SNRIs
• Limited patent protection restrains premium pricing opportunities

What Are the Key Risks and Opportunities in the Investment Landscape?

Risks:

• Declining use due to side-effect profile and availability of newer agents
• Competitive pricing pressures from generic manufacturers
• Regulatory shifts favoring newer treatment paradigms
• Patent and market saturation diminish potential for innovation-driven revenues

Opportunities:

• Growing niche markets: treatment-resistant depression, neuropathic pain
• Potential label expansion for off-label use
• Formulation innovations (e.g., extended-release versions) could command higher prices
• Sudden shifts in clinical guidelines favoring older medications can renew interest

What Are the Financial Trajectories and Outlooks?

Financial forecasts suggest a downward trend for Aventyl Hydrochloride:

Year	Estimated Sales (USD millions)	Factors Influencing
2022	500	Mature generic market, stable demand
2025	400 (projected)	Erosion from newer agents, price competition
2030	250 (projected)	Continued market share decline, generics normalization

Limited exclusive marketing rights and the absence of new formulations will constrain revenue growth. An aging patent landscape favors commoditization, pushing prices downward over time.

What Is the Investment Outlook?

Investment in Aventyl Hydrochloride as a standalone asset offers limited growth prospects absent innovation or market expansion initiatives. The focus remains on niche utilization and stability in generic markets rather than growth.

Pharmaceutical firms might consider investments in reformulation or combination therapies that leverage existing knowledge but are unlikely to generate significant revenues solely from Aventyl Hydrochloride.

Key Takeaways

• Aventyl Hydrochloride is a generic tricyclic antidepressant active since the 1960s, with annual global sales between USD 400-600 million.
• The market is dominated by newer antidepressants, leading to declining market share for Aventyl.
• Patent expiration around 2010 led to widespread generic competition, eroding pricing power.
• Opportunities exist in niche indications and formulation innovations, but revenue growth remains constrained.
• Financial trajectories forecast declining sales, emphasizing the need to consider alternative strategies for value realization.

FAQs

1. Are there any upcoming regulatory changes that could affect Aventyl Hydrochloride?
   No significant regulatory changes are anticipated; the drug's approval status remains stable for established indications.

2. Could a new formulation revitalize Aventyl Hydrochloride’s market?
   An extended-release or fixed-dose combination formulation could improve tolerability or efficacy, potentially creating a niche, but this requires significant R&D investment and regulatory approval pathways.

3. What are the main competitive advantages of Aventyl Hydrochloride?
   Its efficacy in resistant cases and lower cost as a generic are the main advantages, offsetting its side-effect profile disadvantages.

4. Is market expansion viable for Aventyl Hydrochloride?
   Limited, due to market saturation, patent expiration, and preference for newer classes. Niche indications remain the principal growth area.

5. What investment risks should stakeholders consider?
   Market erosion from newer agents, reimbursement challenges, and lack of innovation limit revenue potential; these factors contribute to a declining financial outlook.

---

Sources

1. IQVIA, Global Psychiatry Market Report, 2022.
2. U.S. Food & Drug Administration (FDA) Drug Approvals Database, 2023.
3. Pharma Intelligence, Antidepressant Market Analysis, 2022.
4. PatentScope, Patent Data for Nortriptyline, 2023.
5. EFPIA/European Medicines Agency, Market Reports, 2022.